Binding Site Expands mAb Portfolio
Binding Site has introduced a number of new monoclonal antibodies targeting infectious diseases, including cytomegalovirus, hepatitis (A, B, C, and D), herpes, human immunodeficiency virus (HIV), rubella, and toxoplasma.
Binding Site’s Immunologicals Group has expanded its monoclonal antibody (mAb) product offerings. In addition to the established conjugated and unconjugated versions of the IgG4 Clone-HP6025 and the CD23 Clone BU-3438, Binding Site has introduced a number of new mAbs targeting infectious diseases, including cytomegalovirus, hepatitis (A, B, C, and D), herpes, human immunodeficiency virus (HIV), rubella, and toxoplasma.
These antibodies are highly specific and demonstrate high levels of purity, extended shelf-life stability, and lot-to-lot consistencies, according to Binding Site. The infectious disease mAbs are all available in a standard-sized 1.0-mg fill format, while the rest come in a standard 0.2-mg fill format. In addition, bulk packaging and customer-specific packaging options are available for all of these mAbs.
Source: Binding Site
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Full Tolerance Coverage Method for Assessing Uniformity of Dosage Units with Large Sample Sizes
March 10th 2025The ‘full tolerance coverage method’ is introduced as a coverage estimation approach for assessing the uniformity of dosage units from large sample sizes, ensuring that no dosage unit exceeds the specification range.
